Adverse events induced by nivolumab and ipilimumab combination regimens.

Kohei SomekawaNobuyuki HoritaAyami KanekoYoichi TagamiNobuhiko FukudaHiromi MatsumotoHo NamkoongYu FujiwaraKaoru MinegishiTakeshi FukumotoKeisuke WatanabeYu HaraNobuaki KobayashTakeshi Kaneko

Published in: Therapeutic advances in medical oncology (2022)

Approximately 40% of patients had grade 3 or higher AE. The N3I1 regimen was substantiated to trigger fewer any AEs, high grade AEs, and serious AE than the N1I3 regimen.

Keyphrases

high grade
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
low grade
patient reported outcomes